- Health Officials Warning Americans of Mosquito-Borne Illness
- Study: Red Meat Possibly Linked to Breast Cancer
- Report: Diabetes Numbers Continue To Rise In US
- AMA Policy Backs Strict E-Cigarette Restrictions
- Healthy Seniors Tested in Bid to Block Alzheimer's
- Study: Antidepressant May Cut Alzheimer's Protein
- The Deer Antler Velvet Supplement Debate
- Five of the Most Dangerous Foods for Young Children
- Johns Hopkins Cancer Center Using $65M Gift for New Patient Care Building
- 10-Year-Old Crossing Items Off 'Vision Bucket List' Before Disease Robs Him of Sight
- Gansler Calls For Manufacturers To Prevent Kids From 'Vaping'
- Recent Study May Provide Key To 'Fountain Of Youth'
- Study: Coffee May Decrease Risk for Type 2 Diabetes
- Study: Laughter May Help Improve Short-Term Memory
- Effective Weight Loss Pill on the Horizon? Study Sees Promising Results
- Groundbreaking Procedure Saves MD Man After Devastating Stroke
- New Treatment Helps Paralyzed Patients Move Again
- Survey: Rate of Uninsured Americans Drops
- National Volunteer Month and the Healing Power Of Dogs
- Encouraging Results from New Drug in Stalling Cancer Growth
- New Non-Invasive Treatment for Atrial Fibrillation Safer, More Effective
- Study: Odd Sleep Schedules May Lead to Irreversible Brain Cell Damage
- States Vote on Restricting Teen Tanning
- Study: Using Acupuncture to Treat Chemo Side Effects for Breast Cancer Patients
- Study to Test 'Chocolate' Pills for Heart Health
- Is the Egg An Essential Part of a Healthy Diet?
- Sinai Hospital Researchers Working to Prevent Heart Attacks
- Researchers: Blood Test Could Predict Alzheimer's in Elderly Patients
- Doctors Hope for Cure in a Second Baby Born With HIV
- 2-Year Extension Seen For Canceled Health Plans
- Diabetes and Risk of Stroke, an Inside Look at the Dangers and Warning Signs
- What is Best: Wild or Farm-Raised Salmon?
- How to Eat Healthy on a Budget
- Indiana Woman Gives Birth to Healthy Boy, Didn't Know She Was Pregnant
- California Senator Seeks Review of Paralysis Cases
- Study Suggests Women Reduce Risk of Cancer By Removing Ovaries by 35
- Polio-Like Illness a Mystery in California
- Maryland Health Benefit Exchange Fires IT Contractor
- MD Official: Listeria Patients Have Recovered
- Maryland Maternity Access Coalition Seeks Statewide Injured Baby Fund
- MD Resets Goal for Health Insurance Enrollment
- Take Action Thursday: Heart Disease
- Asthma in Winter: Tips for Minimizing Attacks
- Healthy Drinks for Kids
- Heart Disease: The Symptoms Many Might Not Recognize
- Doctors at Hopkins Develop Procedure to Cure Excessive Sweating
- Health Exchange Woes to Come Before Md. Board
- Workers, Business Owners Debate Sick-Leave Mandate
- Study: Occasional 'Treat' May Help Overall Weight Loss
- 'Broken Heart Syndrome,' Can Have Symptoms Similar to Heart Attack, Study Finds
- Caffeine Common in Kids, Young Adults; Mainly Soda
- Experts Increasingly Contemplate End of Smoking
- FDA Reconsiders Heart Safety of Common Pain Pills
- First Guidelines Issued to Prevent Stroke in Women
- Frederick Co Mother Fighting for Medical Marijuana for her Children
- Breakthrough in Cancer Research at John's Hopkins Ludwig Center
- NIH Paying Volunteers to Catch the Flu
- Joint Experience Program - Jennifer Gilbert
Encouraging Results from New Drug in Stalling Cancer Growth
Updated: Monday, April 7 2014, 06:24 PM EDT
Two drugs are showing progress in stalling the growth of cancer. One drug, offered by Pfizer, appears to be particularly beneficial, doubling the amount of time in between treatment and tumor growth.
A 165 patient study found that when used in combination with standard treatment, the drug stopped breast cancer cells from growing for nearly two years. That's twice as long as the standard treatment alone.
"It's pretty exciting that in these women who have advanced breast cancer which is either metastasized to other parts of the body or has recurred, that when you give them the standard first line treatment, which is an estrogen blocking pill, and then you add this other drug you can double the time until the cancer comes back," Mercy Oncologist Dr. David Riseberg said.
If approved by the FDA, the treatment would only be available for women with advanced breast cancer, who are estrogen sensitive.
"The question is when is this drug going be available for everybody and that's up to the FDA," Riseberg said. "They have a tough job because on the one hand, they don't want to delay the availability of a drug that could help lots of women on the other hand there are certainly many examples of drugs that look good in small studies but when the larger studies were done there was not an advantage."
Side effects include lower blood cell counts and fatigue. Pfizer has been in talks with the FDA about fast tracking the approval of the drug---eliminating a larger scale study.
Lilly's drug was the other drug studied. It's in the early stages and showed antitumor activity in 33 of 47 patients.